These include the AXL inhibitor BGB324 (also known as R428), currently in a phase 1b study in erlotinib-sensitive and refractory patients with stage III and IV non-small cell lung cancer (NSCLC) [93], and the MerTK inhibitor UNC-2025 [94], which has been reported to block growth of melanoma, NSCLC [95], and other tumor models in preclinical studies [96]. Here, AXL is linked to non-small cell lung carcinoma.